Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026)
Rezolute (RZLT) reported Liabilities and Shareholders Equity of $125.5 million for Q1 2026, up 32.43% on a YoY basis from $94.7 million in Q1 2025, and down 9.5% sequentially from $138.6 million in Q4 2025.
Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Rezolute (RZLT) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $125.5 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 32.43% year-over-year to $125.5 million; the trailing twelve-month figure through Mar 2026 stood at $598.2 million (up 29.24% YoY), and the FY2025 full-year result was $175.5 million, up 32.21% from the prior year.
- Liabilities and Shareholders Equity eased to $125.5 million in Q1 2026, from $138.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $175.5 million in Q2 2025 to a low of $69.6 million in Q1 2022.
- A 5-year average of $126.5 million and a median of $125.5 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity jumped 302.45% in 2022 and plunged 34.62% in 2024, its largest moves.
- Tracing RZLT's Liabilities and Shareholders Equity over 5 years: stood at $150.2 million in 2022, then sank by 31.99% to $102.1 million in 2023, then rose by 9.65% to $112.0 million in 2024, then grew by 23.77% to $138.6 million in 2025, then retreated by 9.5% to $125.5 million in 2026.
- Business Quant data shows RZLT's Liabilities and Shareholders Equity at $125.5 million in Q1 2026, $138.6 million in Q4 2025, and $158.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Rezolute | 31,153.77 | 31,153.77 | - | 125.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.46 Mn |
| Dec 31, 2025 | 138.63 Mn |
| Sep 30, 2025 | 158.66 Mn |
| Jun 30, 2025 | 175.49 Mn |
| Mar 31, 2025 | 94.74 Mn |
| Dec 31, 2024 | 112.01 Mn |
| Sep 30, 2024 | 123.41 Mn |
| Jun 30, 2024 | 132.74 Mn |
| Mar 31, 2024 | 87.74 Mn |
| Dec 31, 2023 | 102.15 Mn |
| Sep 30, 2023 | 113.00 Mn |
| Jun 30, 2023 | 123.72 Mn |
| Mar 31, 2023 | 134.21 Mn |
| Dec 31, 2022 | 150.21 Mn |
| Sep 30, 2022 | 155.99 Mn |
| Jun 30, 2022 | 152.42 Mn |
| Mar 31, 2022 | 69.57 Mn |
| Dec 31, 2021 | 83.41 Mn |
| Sep 30, 2021 | 38.76 Mn |
| Jun 30, 2021 | 42.61 Mn |